Navigation Links
Bridges experimental and bioinformatics perspectives to delineate protein-DNA interactions
Date:2/14/2013

One of the foundations of molecular biology is how the interactions of proteins with DNA control many aspects of gene expression. Since the mid-20th century discoveries of the lac repressor and operator and the competition between the cI and cro proteins for the same segment of DNA, we have learned an enormous amount about the interactions of proteins with DNA and their control of fundamental processes in the cell. An Introduction to ProteinDNA Interactions: Structure, Thermodynamics, and Bioinformatics describes what we know about proteinDNA interactions from the complementary perspectives of molecular and structural biology and bioinformatics and how each perspective informs the others. A particular emphasis is on how insights from experimental work can be translated into specific computational approaches to create unified view of the field and a fuller understanding of proteinDNA interactions.


'/>"/>

Contact: Elizabeth Powers
powerse@cshl.edu
415-422-4101
Cold Spring Harbor Laboratory
Source:Eurekalert  

Page: 1

Related biology news :

1. Nicole George wins 2012 Journal of Experimental Biology Outstanding Paper Prize
2. Experimental drug combination selectively destroys lymphoma cells
3. Experimental gene therapy treatment for Duchenne muscular dystrophy offers hope for youngster
4. The 3rd BGI Bioinformatics Software and Data Release Conference
5. New grant to establish pan-continental bioinformatics research network in Africa
6. An international competition reaffirms the potential of bioinformatics in the diagnosis of disease
7. MARC travel awards announced for the 2012 ISCB Rocky Mountain Bioinformatics Conference
8. Individual perspectives improve laparoscopy
9. Drug interactions wont exclude HCV transplant or HIV co-infected patients from treatment
10. How bacteria change movement direction in response to oxygen: Molecular interactions unravelled
11. Researchers describe new molecular interactions behind the inhibition of TGF beta-signaling
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Bridges experimental and bioinformatics perspectives to delineate protein-DNA interactions
(Date:6/2/2016)... June 2, 2016   The Weather Company , an ... Ads, an industry-first capability in which consumers will be able ... to ask questions via voice or text and receive relevant ... Marketers have long sought an advertising solution ... can be personal, relevant and valuable; and can scale across ...
(Date:5/16/2016)...   EyeLock LLC , a market leader of ... an IoT Center of Excellence in Austin, ... of embedded iris biometric applications. EyeLock,s iris ... security with unmatched biometric accuracy, making it the most ... EyeLock,s platform uses video technology to deliver a fast ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... June 27, 2016  Liquid Biotech ... funding of a Sponsored Research Agreement with The ... cells (CTCs) from cancer patients.  The funding will ... levels correlate with clinical outcomes in cancer patients ... will then be employed to support the design ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology: